# Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors

> **NCT00639262** · PHASE1 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University** · enrollment: 35 (actual)

## Conditions studied

- Brain Metastases
- Primary Brain Tumors

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT00639262
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639262, "Combination of Sorafenib and Radiation for Brain Metastases and Primary Brain Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00639262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*